Medullary carcinoma of the breast

APMIS, Supplement

Volumn 105, Issue 75, 1997, Pages 5-31

  Pedersen, Lise ^b  

^a Medicinsk Historisk Museum   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN D; CELL ADHESION MOLECULE; CYTOKERATIN 19; DNA; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; PROTEIN P53; VIMENTIN;

ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER SURVIVAL; CELL CYCLE S PHASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; INTRADUCTAL CARCINOMA; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; BREAST TUMOR; CHEMISTRY; FEMALE; MEDULLARY CARCINOMA; MORTALITY; PATHOLOGY; SURVIVAL RATE;

BREAST NEOPLASMS; CARCINOMA, MEDULLARY; DNA, NEOPLASM; FEMALE; HUMANS; PROGNOSIS; SURVIVAL RATE;

EID: 0031439465     PISSN: 0903465X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0463.1997.tb05606.x     Document Type: Article

References (81)

1. Andersen, K.W., Mouridsen, H.T., Castberg, T., Fischerman, K., Andersen, J., Hou-Jensen, K., Brincker, H., Johansen, H., Henriksen, E., Rorth, M., Rossing, N. Organisation of the Danish adjuvant trials in breast cancer. Dan. Med. Bull. 28:102-106, 1981.
2. Andersen, K.W., Mouridsen, H.T. Danish Breast Cancer Cooperative Group (DBCG). Acta Oncol (Fasc 6a) 27: 627-647, 1988.
3. Andersen, P.K., Væth, M. Statistisk analyse af overlevelses-data ved lægevidenskabelige undersogelser. FADL's Forlag, Copenhagen 1984.
4. Armas, O.A., Gerald, W.L., Lesser, M.L., Arroyo, C.D., Norton, L., Rosen, P.P. Immunohistochemical detection of Cathepsin D in T2 N0 M0 breast carcinoma. Am. J. Surg. Pathol. 18: 158-166, 1994.
5. Axelsson, C.K., Mouridsen, H.T., Zedeler, K. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. Eur. J. Cancer 28 A: 1415-1418, 1992.
6. Bacus, S.S., Zelnick, C.R., Chin, D.M., Yarden, Y., Kaminsky, D.B., Bennington, J., Wen, D., Marcus, J.N., Page, D.L. Medullary carcinoma is associated with expression of intercellular Adhesion Molecule-1. Am. J. Pathol. 145:1337-1348, 1994.
7. Balslev, I., Christensen, I.J., Rasmussen, B.R., Larsen, J.K., Lykkesfeldt, A.E., Thorpe, S.M., Rose, C., Briand, P., Mouridsen, H.T. Flow Cytometric DNA Ploidy Defines Patients With Poor Prognosis in Node-Negative Breast Cancer. Int. J. Cancer 56:16-25, 1994.
8. Ben-Ezra, J., Sheibani, K. Antigenic phenotype of the lym-pho-cytic component of medullary carcinoma of the breast. Cancer 59:2037-2041, 1987.
9. Bergers, E., Diest, P. J.v., Baak, J.P.A. Cell Cycle Analysis of 932 Flow Cytometric DNA Histograms of Fresh Fresh Frozen Breast Carcinoma Material. Cancer 77: 2258-66, 1996.
10. Bloom, H.J.G., Richardson, W.W. Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br. J. Cancer 11:359-377, 1957.
11. Bloom, H.J.G., Richardson, W.W., Field, J.R. Host resistance and survival in carcinoma of the breast: A study of 104 cases of medullary carcinoma in a series of 1,411 cases of breast cancer followed for 20 years. Br. Med. J. 3:181-188, 1970.
12. Bosari, S., Lee, A.K.C., DeLellis, R.A., Wiley, B.D., Heatly, G.J., Silverman, M.L. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum. Pathol. 23:755-761, 1992.
13. Camplejohn, R.S., Ash, C.M., Gillet, C.E., Raikundalia, B., Barnes, D.M., Gregory, W.M., Richards, M.A., Millis, R.R. The prognostic significance of DNA flow cytometry in breast cancer: results from 881 patients treated in a single centre. Br. J. Cancer 71:140-145.
14. Carter, D., Pipkin, R.D., Shepard, R.H. Relationship of necrosis and tumor border to lymph node metastases and 10-year survival in carcinoma of the breast. Am. J. Surg. Pathol. 2:39-46, 1978.
15. Christensen, I, Hartmann, N.R., Keiding, N., Larsen, J.K., Noer, H., Vindelov, L. Statistical analysis of DNA distribution from cell populations with partial synchrony. In: Lutz, D. (ed) Pulse-Cytophotometry III. European Press, Ghent, 1978, pp 519-526.
16. Cohen, J. A coefficient of agreement for nominal scales. Educat. Psychol. Measurement 20:37-46, 1960.
17. Cook, D.L., Weaver, D.L. Comparison of DNA Content, S-Phase Fraction, and Survival between Medullary and Ductal Carcinoma of the Breast. Am. J. Clin. Pathol. 104:17-22, 1995.
18. Cox, D.R. Regression models and life-tables. J. Roy. Statist. Soc. Sect. 334:187-200, 1972.
19. Cutler, S.J., Black, M.M., Friedell, G.H., Vidone, R.A., Goldenberg, I.S. Prognostic factors in cancer of the female breast. II. Reproducibility of histopathologic classification. Cancer 19:75-82, 1966.
20. Delides, G.S., Garas, G., Georgouli, G., Jiortziotis, D., Lecca, J., Liva, T., Elemenoglou, J. Intralaboratory variations in the grading of breast carcinoma. Arch. Pathol. Lab. Med. 106:126-128, 1982.
21. Domagala, W., Lasota, J., Dukowicz, A., Markiewski, M., Striker, G., Weber, K., Osborn, M. Vimentin expression appears to be associated with poor prognosis in node-negative ductal NOS breast carcinomas. Am. J. Pathol. 137:1299-1304, 1990a.
22. Domagala, W., Wozniak, L., Lasota, J., Weber, K., Osborn, M. Vimentin is preferentially expressed in highgrade ductal and medullary, but not in lobular breast carcinomas. Am. J. Pathol. 137:1059-1064, 1990b.
23. Domagala, W., Harezga, B., Szadowska, A., Markiewski, M., Weber, K., Osborn, M. Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas. Am. J. Pathol. 142:669-674, 1993.
24. Domagala, W., Striker, G., Szadowska, A., Dukowicz, A., Harezga, B., Osborn, M. p53 protein and Vimentin in invasive ductal NOS breast carcinoma - Relationship with survival and sites of metastases. Eur. J. Cancer 30A: 1527-1534, 1994.
25. Dressier, L.G. Are DNA Flow Cytometry Measurements Providing Useful Information in the Management of the Node-Negative Breast Cancer Patient. Cancer Invest. 10(5): 477-486, 1992.
26. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1-15, 1992a.
27. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:71-85, 1992b.
28. Ewers, S. Flow Cytometric DNA Analysis in Breast Cancer-Prospective evaluation of Prognosis and Prediction of Treatment Effects. Thesis. Lund, 1992. Grahns Bocktryckeri, Sweden, 1992.
29. Ewertz, M. Breast Cancer in Denmark - Incidence, risk factors, and characteristics of survival. Thesis. University of Copenhagen. Copenhagen, 1993.
30. Fernö, M., Baldetorp, B., Borg, Å., Olsson, H., Sigurdsson, H., Killander, D. Flow Cytometric DNA Index and SPhase Fraction in Breast Cancer in Relation to Other Prognostic Variables and to clinical Outcome. Acta Oncol. 31:157-165, 1992.
31. Fisher, E.R., Gregorio, R.M., Fisher, B. The pathology of invasive breast cancer. Cancer 36:1-84, 1975.
32. Fisher, E.R. Comment on "Interobserver reproducibility of histopathological features in Stage II breast cancer", by K.W. Gilchrist et al. Breast Cancer Res. Treat. 5:11-13, 1985.
33. Fisher, E.R., Kenny, J.P., Sass, R., Dimitrov.N.V., Siderits, R.H., Fisher, B. Medullary cancer of the breast revisited. Breast Cancer Res. Treat. 16:215-229, 1990a.
34. Fisher, E.R., Redmond, C., Fisher, B., Bass, G. Pathologic findings from the National Surgical Adjuvant Breast and Bowel projects (NSABP). Cancer 65: 2121-2128, 1990b.
35. Foote, F.W., Stewart, F.W. A histologie classification of carcinoma of the breast. Surgery 19:74-99, 1946.
36. Frierson, H.F. Ploidy Analysis and S-Phase Fraction Determination by Flow Cytometry of Invasive Adenocarcinomaes of the Breast. Am. J. Surg. Pathol. 15(4): 358-367, 1991.
37. Gaffey, M.J., Mills, S.E., Frierson, H.F., Zarbo, R.J., Boyd, J.C., Simpson, J.F., Weiss, L.M. Medullary carcinoma of the breast: Interobserver variability in histopathologic diagnosis. Modern Pathol. 8:31-38, 1995.
38. Gaffey, M. J., Frierson, H.F., Mills, S.E., Boyd, J.C., Zarbo, R.J., Simpson, J.F., Gross, L.K., Weiss, L.M. Medullary carcinoma of the breast - Identification of lymphocyte sub-populations and their significance. Modern Pathol. 6:721-728, 1993.
39. Gilchrist, K.W., Kalish, L., Gould, V.E., Hirschl, S., Imbriglia, J.E., Levy, W.M., Patchefsky, A.S., Penner, D.W., Pickren, J., Roth, J.A., Schinella, R.A., Schwartz, I.S., Wheeler, J.E. Interobserver reproducibility of histopathological features in stage II breast cancer. Breast Cancer Res. Treat. 5:3-10, 1985.
40. Gjorup, T. Klinisk vurdering af diagnostiske undersøgelsesmetoder. Thesis. Lgeforeningens Forlag, Copenhagen, 1988.
41. Gorski, C.M., Niepolomska, W., Nowak, K., Gebel, B., Plewa, T., Pysz, H., Adamus, J. Clinical evaluation and pathological grading in relation to other prognostic factors. In: Prognostic factors in breast cancer. Forrest & Kunkler (eds) pp 309-318, Williams and Wilkins, 1968.
42. Hedley, D.W., Friedlander, M.L., Taylor, I.W., Rugg, C.A., Musgrove, E.A. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J. Histochem. Cytochem. 31: 1333-1335, 1983.
43. Hedley, D.W. DNA flow cytometry and breast cancer. Breast Cancer Res. Treat. 28:51-53.
44. Hedley, D.W., Clark, G.M., Cornelisse, C.J., Killander, D., Kute, T., Douglas, M. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Breast Cancer Res. Treat. 28:55-59, 1993.
45. Helin, H.J., Helle, M.J., Kallioniemi, O.-P., Isola, J.J. Immunohistochemical determination of estrogen and progesterone receptors in human breast carcinoma - Correlation with histopathology and DNA flow cytometry. Cancer 63:1761-1767, 1989.
46. Hoick, S., Pedersen, L., Schiodt, T., Zedeler, K., Mouridsen, H. Vimentin expression in 98 breast cancers with medullary features and its prognostic significance. Virchows Archiv A Pathol Anat 422:475-479, 1993.
47. Hurlimann, J., Gebhard, S., Gomez, F. Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas. Histopathology 23:239-248, 1993.
48. Kandalaft, P.L., Chang, K.L., Ahn, C.W., Traweek, S.T., Mehta, P., Battifora, H. Prognostic significance of immunohisto-chemical analysis of Cathepsin D in lowstage breast cancer. Cancer 71:2756-2763, 1993.
49. Kurtz, J.M., Jacquemier, J., Torhorst, J., Spitalier, J.-M., Amalric, R., Hünig, R., Walther, E., Harder, F., Almendral, A., Brandone, H., Ayme, Y., Roth, J. Conservation therapy for breast cancers other than infiltrating ductal carcinoma. Cancer 63:1630-1635, 1989.
50. Kute, T.E., Quadri, Y., Muss, H., Zbieranski, N., Cirrincione, C., Berry, D.A., Barcos, M., Thor, A.P., Liu. F., Koemer, F., Henderson, I.C. Flow Cytometry in Node-Positive Breast Cancer: Cancer and Leukemia Group B Protokol 8869. Cytometry 22:297-306, 1995.
51. Landis, J.R., Koch, G.G. The measurement of observer agreement for categorical data. Biometrics 53: 159-174, 1977.
52. Langley, F.A. Quality control in histopathology and diagnostic cytology. Histopathology 2:3-18, 1978.
53. Larsimont, D., Lespagnard, L., Degeyter, M., Heimann, R. Medullary carcinoma of the breast: a tumour lacking keratin 19. Histopathology 24:549-552, 1994.
54. Maier, W.P., Rosemond, G.P., Goldman, L.I., Kaplan, G.F., Tyson, R.R. A ten year study of medullary carcinoma of the breast. Surg. Gynecol. Obstet. 144: 695-698, 1977.
55. Mitze, M., Goepel, E. Prognostische Faktoren beim medulloren Mammakarzinom. Geburtsh. u. Frauenheilk. 49:635-641, 1989.
56. Moore, O.S. Jr., Foote, F.W. The relatively favorable prognosis of medullary carcinoma of the breast. Cancer 2: 635-642, 1949.
57. Ottesen, G.L., Christensen, I.J., Larsen, J.K., Larsen, J., Christiansen, J., Baldetorp, B., Linden, T., Hansen, B., Andersen, J .A. DNA ploidy in breast cancer: A comparison of unfixed and fixed tissue, by image and flow cytometry. Anal Quant. Cytol. Histol. In press, March 1997
58. Pedersen, L., Hoick, S., Schiodt, T. Medullary carcinoma of the breast. Cancer Treat. Rev.15:53-63, 1988.
59. Pujol, P., Maudelonde, T., Daures, J.-P., Rouanet, P., Brouillet, J.-P., Pujol, H., Rochefort, H. A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol. Cancer 71:2006-2012, 1993.
60. Rank, F., Dombernowsky, P., Jespersen, N.C.B., Pedersen, B.V., Keiding, N. Histologie malignancy grading of invasive ductal breast carcinoma. - A regression analysis of prognostic factors in low-risk carcinomas from a multicenter trial. Cancer 60:1299-1305, 1987.
61. Rapin, V., Contesso, G., Mouriesse, H., Bertin, F., Lacombe, M.J., Piekarski, J.D., Travagli, J.P., Gadenne, C., Friedman, S. Medullary breast carcinoma - A reevaluation of 95 cases of breast cancer with inflammatory stroma. Cancer 61:2503-2510, 1988.
62. Reiner, A., Reiner, G., Spona, J., Schemper, M., Holzner, J.H. Histopathologic characterization of human breast cancer in correlation with estrogen receptor status. Cancer 61:1149-1154, 1988.
63. Richardson, W.W. Medullary carcinoma of the breast. Br. J. Cancer 10:415-426, 1956.
64. Ridolfi, R.L., Rosen, P.P., Port, A., Kinne, D., Miké, V. Me-dullary carcinoma of the breast. Cancer 40: 1365-1385, 1977.
65. Rigaud, C., Theobald, S., Noël, P., Badreddine, J., Barlier, C., Delobelle, A., Gentile, A., Jacquemier, J., Maisongrosse, V., Peffault de Latour, M., Trojani, M., Zafrani, B. Medullary carcinoma of the breast. Arch. Pathol. Lab. Med. 117:1005-1008, 1993.
66. Rochefort, H. Cathepsin D in breast Cancer: A Tissue marker associated with metastasis. Eur. J. Cancer 28A: 1780-1783.
67. Schiødt, T. Breast Carcinoma. Thesis. University of Copenhagen. Munksgaard, 1966.
68. Schutte, B., Reynders, M.M.J., Bosman, F.T., Blijham, G.H. Flow cytometric determination of DNA ploidy level in nuclei isolated from paraffin-embedded tissue. Cytometry 6:26-30, 1985.
69. Stenkvist, B., Westman-Naeser, S., Vegelius, J., Holmquist, J., Nordin, B., Bengtsson, E., Eriksson, O. Analysis of reproducibility of subjective grading systems for breast carcinoma. J. Clin. Pathol. 32:979-985, 1979.
70. Shankey, T.V., Rabinovitch, P.S., Bagwell, B., Bauer, K.D., Cox, C., Duque, R.E., Hedley, D.W., Mayall, B.H., Wheeless, L. Guidelines for the implementation of clinical DNA cytometry. Breast Cancer Res. Treat. 28: 61-68, 1993.
71. Svanholm, H., Starklint, H., Gundersen, H.J.G., Fabricius, J., Barlebo, H., Olsen, S. Reproducibility of histomorphologic diagnoses with special reference to the kappa statistic. APMIS 97:689-698, 1989.
72. Tanaka, H., Hori, M., Ohki, T. High endothelial venule and immunocompetent cells in typical medullary carcinoma of the breast. Virchows Archiv A Pathol. Anat. 420:253-261, 1992.
73. Wargotz, E.S., Silverberg, S.G. Medullary carcinoma of the breast.: A Clinicopathologic study with appraisal of current diagnostic criteria. Hum. Pathol. 19: 1340-1346, 1988.
74. UICC Technical Report Series. An International Survey of Distributions of histologie types of breast cancer. P. Correa and William D. Johnson (eds.), vol. 35. UICC, Geneva 1978.
75. Vindeløv, L.L., Christensen, I. J. A review of techniques and results obtained in one laboratory by an integrated system of methods designed for routine clinical flow cytometric DNA analysis. Cytometry 11:753-770, 1990.
76. Visscher, D.W., Zarbo, R.J., Greenawald, K.A., Crissman, J.D. Prognostic Significance of Morphological Parameters and Flow Cytometric DNA Analysis in Carcinoma of the Breast. Pathol-Annu 25: 171-210, 1990.
77. Weidner,N., Folkman, J., Pozza, F., Bevilacqua, P., Allred, E.N., Moore, D.H., Meli, S., Gasparini, G. Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst. 84:1875-1887, 1992.
78. Weidner, N. Tumor angiogenesis: Review of current applications in tumor prognostication. Sem. Diagn. Pathol. 10:302-313, 1993.
79. WHO. Histological Typing of Breast Tumours. Scarff & Torloni (eds). World Health Organization, Geneva, 1968.
80. WHO. Histological Typing of Breast Tumours. 2nd ed., World Health Organization, Geneva, 1981.
81. Zedeler, K. Assessment and presentation of survival experience in the Danish Breast Cancer Cooperative Group. Acta Oncol (Fasc. 6a) 27:649-662, 1988.